Literature DB >> 17118710

Endotoxin apheresis for sepsis.

Tomoharu Shimizu1, Yoshihiro Endo, Hiroshi Tsuchihashi, Hiroya Akabori, Hiroshi Yamamoto, Tohru Tani.   

Abstract

The principle use of apheresis in the treatment of sepsis may be summarized as the removal of toxic substances and the restoration of normal organs function. It is ideal to control the early phases of inflammatory cascade when treating sepsis by removing microbial components, such as endotoxin or peptidoglycan. This review discusses endotoxin apheresis with particular emphasis on treatment using polymyxin B immobilized fiber columns (Toraymyxin) which are used widely in Japan for endotoxin removal therapy in patients with septic shock. Lixelle and CTR which have recently been shown to remove circulating bacterial components are also included in this review.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118710     DOI: 10.1016/j.transci.2006.06.006

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

1.  Efficacy of a novel endotoxin adsorber polyvinylidene fluoride fiber immobilized with (L)-serine ligand on septic pigs.

Authors:  Jian-ping Gao; Man Huang; Ning Li; Peng-fei Wang; Huan-Lin Chen; Qiu-ping Xu
Journal:  J Zhejiang Univ Sci B       Date:  2011-04       Impact factor: 3.066

2.  Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation.

Authors:  Tomoharu Shimizu; Kazuyoshi Hanasawa; Koichi Sato; Masahiko Umeki; Nobuhiko Koga; Tatsushi Naganuma; Seiji Sato; Tomonori Shimonishi; Toshiaki Ikeda; Naoto Matsuno; Satoshi Ono; Hitoshi Saitoh; Koshi Satoh; Yoshimasa Otani; Yoshihiro Endo; Yutaka Eguchi; Tohru Tani
Journal:  Langenbecks Arch Surg       Date:  2008-08-07       Impact factor: 3.445

Review 3.  New approaches to the study of sepsis.

Authors:  Peter A Ward
Journal:  EMBO Mol Med       Date:  2012-12       Impact factor: 12.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.